A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 100
- Population
- ALL · 50 Years
- Duration
- 2007-01-01 to 2007-09-01
- Intervention
- Avastin; Photodynamic Therapy (PDT); Preservative-Free Triamcinolone Acetonide (TAC-PF)
- Comparator
- Not reported
- Outcomes measured
- The mean change in best-corrected ETDRS visual acuity in the study eye from baseline to month 12; Mean and median change in ETDRS BCVA from baseline to months 3, 6, and 24.; Proportion of participants avoiding a loss of ³ 15 letters in ETDRS BCVA by months 3, 6, 12, and 24; Proportion of participants improving by ³ 15 letters in ETDRS BCVA at months 3, 6, 12, and 24.; Proportion of participants who show any improvement in ETDRS BCVA at months 3, 6, 12, and 24.; Mean change in the total lesion area (Disc Areas) from baseline to months 3, 6, 12, and 24.; Mean change in area of CNV (Disc Areas) at months 3, 6, 12, and 24.; Mean change in area of leakage (Disc Areas) at months 3, 6, 12, and 24.; Proportion of classic CNV out of the entire lesion from baseline to months 3, 6, 12, and 24.; Changes in mean excess retinal thickening in the center subfield (i.e., thickness >175 microns) from baseline to months…; Proportion of participants with reduction in retinal thickening in the center subfield (i.e., thickness > 175 microns)…; The overall probability of re-injection (excluding injections precluded for safety concerns) through Month 12.; The mean number of injections by quarter on study following initial induction injections.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.